Flawless Formulation. Effortless Access. Evolysse™ combines advanced Cold-X™ Technology with injectable hyaluronic acid science, designed to feel natural in the face.
After submitting your details, you’ll receive an email with the next steps.
Evolysse™ redefines what’s possible in injectable hyaluronic acid science. Pipeline Medical transforms how you get it.
Available Now
Available Now
Medical practices face increasing patient demands for natural-looking aesthetic outcomes. Today’s patients arrive more informed than ever before, researching treatment options extensively before consultation. They seek results that enhance their appearance without sacrificing authenticity or natural movement. This creates a significant challenge for medical professionals: delivering consistently excellent outcomes that meet these heightened expectations.
Traditional injectable hyaluronic acid (HA) fillers often present limitations in dynamic facial areas. Medical professionals frequently report compromises between achieving desired volume and maintaining natural movement, especially when treating nasolabial folds and other expressive facial regions. When patients express dissatisfaction with results that appear “overdone” or feel unnatural during facial expressions, it impacts both patient retention and practice reputation.
The connection between effective aesthetic products and medical practice success extends beyond individual treatments. Each patient interaction represents potential long-term value, with satisfied patients returning for maintenance treatments and referring colleagues and friends. Conversely, suboptimal results may lead to costly corrective procedures, decreased trust, and potential reputation damage in today’s review-driven marketplace.
Medical practices face increasing patient demands for natural-looking aesthetic outcomes. Today’s patients arrive more informed than ever before, researching treatment options extensively before consultation. They seek results that enhance their appearance without sacrificing authenticity or natural movement. This creates a significant challenge for medical professionals: delivering consistently excellent outcomes that meet these heightened expectations.
Traditional injectable hyaluronic acid (HA) fillers often present limitations in dynamic facial areas. Medical professionals frequently report compromises between achieving desired volume and maintaining natural movement, especially when treating nasolabial folds and other expressive facial regions. When patients express dissatisfaction with results that appear “overdone” or feel unnatural during facial expressions, it impacts both patient retention and practice reputation.
The connection between effective aesthetic products and medical practice success extends beyond individual treatments. Each patient interaction represents potential long-term value, with satisfied patients returning for maintenance treatments and referring colleagues and friends. Conversely, suboptimal results may lead to costly corrective procedures, decreased trust, and potential reputation damage in today’s review-driven marketplace.
The dermal filler market has undergone significant transformation since the first FDA-approved hyaluronic acid fillers became available in the early 2000s. Initially, products emphasized volume correction, sometimes at the expense of natural movement in dynamic facial areas. As patient expectations evolved, the demand for more sophisticated solutions increased.
Medical professionals understand this evolution well. Early-generation HA fillers presented several limitations:
Recent years have seen HA dermal filler manufacturers focus on addressing these challenges through advanced research and development. However, until now, most improvements have been incremental rather than revolutionary. Medical professionals and patients alike have anticipated a more significant leap forward in hyaluronic acid science that would maintain correction while enhancing natural movement and feel.
Hyaluronic acid is a naturally occurring substance in the human body that provides volume, hydration, and structure to the skin. Its remarkable capacity to bind water molecules—up to 1,000 times its weight—makes it an ideal substance for addressing volume loss and supporting dermal structure.
In dermal fillers, the natural hyaluronic acid undergoes crosslinking—a process that connects the HA molecules to create a stable gel matrix that resists rapid degradation by the body’s natural enzymes. The specific crosslinking methods, concentration of HA, and manufacturing processes significantly impact the final product’s characteristics, including:
These characteristics ultimately determine how the filler performs in various facial regions and how naturally it moves with the patient’s expressions. The ideal filler maintains volume correction while preserving natural facial dynamics—a balance that has proven challenging to achieve consistently with traditional technologies.
Against this backdrop of incremental advancements, Evolus® announces the official launch of their groundbreaking product. The new offering represents the first major technological breakthrough in HA dermal fillers in a decade. This revolutionary platform represents a significant advancement in the HA dermal filler market, utilizing proprietary Cold-X™ Technology designed specifically to preserve the natural HA structure, addressing longstanding challenges in achieving natural-looking results that feel natural in the facial tissue when treating wrinkles and folds.
The development of Cold-X™ Technology began with a fundamental question: How can manufacturing processes better preserve the natural characteristics of hyaluronic acid? Traditional crosslinking methods often expose HA molecules to conditions that can potentially alter their biological properties.
The research team at Symatese, through an exclusive agreement with Evolus®, explored alternative approaches that would maintain the essential structure of hyaluronic acid throughout processing. After extensive research and development, they created a proprietary method that:
Cold-X™ Technology represents a fundamental shift in how injectable hyaluronic acid gels are manufactured. Traditional manufacturing processes subject HA molecules to conditions that can potentially alter their natural structure. Cold-X™ Technology, through an agreement with Symatese, takes a different approach by:
This technology, specifically aimed at preserving the natural structure of hyaluronic acid, allows the injectable hyaluronic acid made with Cold-X Technology to be designed to feel natural when used to treat wrinkles that form in dynamic areas of the face.
The EVOLYSSE™ collection includes the first two products to receive FDA approval, with additional options to address different facial rejuvenation needs:
EVOLYSSE™ Form: Specifically developed for moderate to severe facial wrinkles and folds, including nasolabial folds. This smooth injectable hyaluronic acid gel provides structural support while maintaining natural movement in form in dynamic areas.
EVOLYSSE™ Smooth: Designed for areas requiring subtle enhancement with exceptional integration into surrounding tissue. This formulation of smooth injectable HA gels excels in regions where maintaining natural movement is paramount.
EVOLYSSE™ Lift: Completes the EVOLYSSE™ collection with specialized properties for areas requiring both lift and volumization while preserving natural facial dynamics.
Each of these two injectable HA gels leverages Cold-X™ Technology to achieve results that previous generation fillers like Restylane-L struggled to balance: effective correction with natural feel and movement.
In a recent press release, Evolus® announces FDA approval of EVOLYSSE™ Form and EVOLYSSE™ Smooth injectable hyaluronic acid gels following rigorous clinical evaluation. The NLF pivotal study included 140 patients and showed statistically significant differences in treatment outcomes compared to control products, including:
Dr. Rui Avelar, Chief Medical Officer at Evolus®, emphasizes that “EVOLYSSE™ represents the culmination of years of research aimed at preserving the natural structure of hyaluronic acid throughout the manufacturing process, resulting in EVOLYSSE™ fillers that perform exceptionally in dynamic facial areas. The ability of these products to maintain their integrity while allowing natural movement is a direct result of our reliance on Symatese to achieve this technological breakthrough in HA dermal fillers.”
The new collection from Evolus® brings several distinct advantages to medical practices seeking to elevate their aesthetic offerings:
Medical professionals considering incorporating these advanced fillers into their practice protocols should understand several key aspects of implementation:
While the fundamental injection techniques used for these new-generation fillers remain consistent with established methods, practitioners may notice differences in:
Experienced injectors typically adapt quickly to these nuances after treating their first few patients. Many report that the improved consistency and predictability of these advanced formulations actually simplifies the injection process once they become familiar with the products’ handling characteristics.
Optimal candidates for these new fillers include:
When discussing these advanced options with patients, medical professionals should emphasize:
Providing educational materials that explain the science behind these advancements in terms accessible to patients helps build confidence in both the product and the practitioner’s expertise.
The FDA approval of EVOLYSSE™ Form and EVOLYSSE™ Smooth injectable hyaluronic acid gels validates both their safety and effectiveness for use in the U.S. market. The clinical studies supporting approved EVOLYSSE™ showed:
As with all injectable HA gels, medical professionals should review complete safety information and contraindications before use of these products. EVOLYSSE™ is contraindicated for patients with severe allergies, and safety for use during pregnancy or while breastfeeding has not been established. Additionally, patients should be advised to report any unusual pain during or shortly after treatment, and the product should be used with caution in patients taking medication that can prolong bleeding.
David Moatazedi, President and CEO of Evolus®, states: “The launch of EVOLYSSE™ represents a significant milestone for Evolus® and for the aesthetics industry. We’ve delivered the first major technological breakthrough in HA dermal fillers in a decade, providing medical professionals with next-generation hyaluronic acid injectable gels powered by cutting-edge Cold-X™ Technology to achieve exceptional results for their patients.”
Medical professionals from Newport Beach who participated in clinical trials report that EVOLYSSE™ products offer improved moldability and integration compared to previous generation fillers. “These injectable gels powered by cutting-edge Cold-X™ Technology allow us to achieve natural-looking results when treating facial wrinkles and folds, representing a meaningful advance in how we approach facial rejuvenation,” noted one leading aesthetic specialist.
Medical professionals frequently ask how this innovative technology differs from conventional approaches to HA filler manufacturing. The key distinctions include:
Temperature-Controlled Processing: Unlike traditional methods that may expose hyaluronic acid to higher temperatures during production, Cold-X™ Technology maintains lower, controlled temperature parameters throughout manufacturing. This preservation of the natural HA molecule structure contributes to the product’s distinctive performance characteristics.
Molecular Integrity: The technology is specifically designed to preserve the natural structure of the HA molecule during crosslinking. This results in a more biologically compatible gel that integrates more harmoniously with facial tissues.
Balanced Performance: Products developed with this technology achieve an optimal balance between structural support and natural movement—a combination that has proven challenging with conventional manufacturing methods.
Tissue Integration: The preserved molecular structure facilitates enhanced integration with surrounding tissues, contributing to a more natural feel and appearance.
Understanding the optimal applications for these next-generation products helps medical professionals make appropriate recommendations for their patients:
Dynamic Facial Areas: These fillers are particularly well-suited for regions with significant movement, such as nasolabial folds, marionette lines, and areas around the mouth.
Patients Prioritizing Natural Results: For patients who express concerns about maintaining natural expressions or those who have experienced “stiff” or unnatural results with previous fillers.
Combination Treatments: These products work exceptionally well as part of comprehensive facial rejuvenation protocols, complementing other aesthetic treatments like neurotoxins, energy-based devices, and topical skincare.
First-Time Filler Patients: The natural-feeling results can help build confidence in patients new to injectable treatments, potentially increasing satisfaction and retention.
Integrating these advanced fillers into established treatment protocols is straightforward for experienced practitioners:
Assessment Approach: The fundamental patient assessment process remains consistent, focusing on facial anatomy, volume loss patterns, skin quality, and patient goals.
Injection Technique: While the basic injection techniques are similar to those used with traditional HA fillers, practitioners may notice differences in extrusion force and product distribution that typically require minor adjustments.
Product Selection: Understanding the specific characteristics of each formulation in the collection allows practitioners to match the appropriate product to each treatment area and correction need.
Follow-up Protocols: Standard follow-up timelines apply, though practitioners report that the consistent performance of these products may allow for more predictable maintenance scheduling.
Effective patient education enhances satisfaction and builds trust. Resources available through Pipeline Medical include:
Before and After Galleries: Comprehensive collections of clinical images demonstrating results across diverse patient populations and treatment areas.
Technology Explainers: Patient-friendly materials explaining how Cold-X™ Technology differs from traditional approaches and the benefits this provides.
Treatment Planning Guides: Resources to help patients understand the comprehensive approach to facial rejuvenation and how these advanced fillers contribute to overall outcomes.
Post-Treatment Care Instructions: Detailed guidance for optimal recovery and result longevity following treatment with these next-generation products.
Pipeline Medical‘s marketplace simplifies access to EVOLYSSE™ products through our specialized supply chain procurement platform. Our streamlined system eliminates traditional procurement challenges by:
Medical professionals can maximize the benefits of EVOLYSSE™ by:
Pipeline Medical offers comprehensive support for medical practices implementing EVOLYSSE™ into their treatment protocols:
The development of Cold-X™ Technology demonstrates how fundamental innovation can address longstanding challenges in aesthetic medicine. By preserving the natural HA structure, EVOLYSSE™ creates new possibilities for:
EVOLYSSE™ raises expectations for what patients and providers should expect from dermal fillers:
The introduction of EVOLYSSE™ builds upon Evolus®’ established position in aesthetic medicine, following their successful launch of Jeuveau®, the first and only neurotoxin dedicated exclusively to aesthetics. This pattern of innovation demonstrates the company’s commitment to developing specialized solutions for aesthetic practitioners and their patients.
Through their strategic reliance on Symatese to achieve regulatory approval for this technological breakthrough in HA dermal fillers, Evolus® continues to demonstrate their focus on bringing meaningful advancements to the medical aesthetics community.
The introduction of EVOLYSSE™ Form and EVOLYSSE™ Smooth injectable hyaluronic acid gels powered by cutting-edge Cold-X™ Technology represents a significant opportunity for medical practices to enhance their aesthetic services. By offering EVOLYSSE™ Smooth and EVOLYSSE™ Form, these next-generation products developed by Symatese, practices can:
Discover how Pipeline Medical’s marketplace can streamline your practice’s procurement process for the EVOLYSSE™ collection. Access FDA-compliant medical-grade products through our supply chain procurement platform to enhance your practice’s capabilities and patient satisfaction.
The information provided on this site is for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider or medical professional for guidance on any medical concerns, product use, or treatment decisions.
At Pipeline Medical, we simplify your ordering so that you can focus on patient care.
Join the growing number of aesthetic professionals who are simplifying their sourcing with Pipeline Medical.